Expedeon signs supply and license agreement for is Lightning-Link technology
The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.
Expedeon has signed a supply and license agreement with Cell Guidance Systems, a developer of therapeutic products for medicine and life science research, for use of Expedeon’s proprietary Lightning-Link Rapid Biotin technology in the development and production of TRIFic (Time Resolved Immunofluorescence Exosome Detection Assay) immunoassays. Cell Guidance Systems has already benefitted from the application of Expedeon’s Lightning-Link technology for more than 2 years, and under this new agreement Expedeon becomes preferred immunoreagent supplier to the company
Cell Guidance Systems’ TRIFic rapid detection assay provides quantitative data from purified and unpurified samples, including direct measurements of exosomes in plasma. TRIFic exosome assays are available for widely used markers of exosomes, including the tetraspanin proteins CD9, CD63 and CD81, and provides high sensitivity detection levels which are clear and consistent over a wide range of samples.
The Expedeon Lightning-Link Rapid Biotin kit enables the rapid, direct biotinylation of antibodies, proteins and peptides, or any other biomolecule with an available amine group, with 100% recovery of materials. The kit is optimized for assays in which the biotinylated protein is captured by streptavidin immobilized on a surface. The kit requires only 30 seconds hands-on time and the conjugates are ready to use in under 20 minutes. The technology is fully scalable from 10 ug to 1 g or over, and is stringently QC tested for consistent high quality and excellent batch-to-batch reproducibility.
Using Expedeon’s Lightning-Link biotin technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results. Cell Guidance Systems will benefit from cost savings on detection antibodies and secondary immunoreagents, plus improved production yields and enhanced quality of immunoassay handling.
Dr Heikki Lanckriet, CEO and CSO of Expedeon, commented: “We have been working with Cell Guidance Systems for several years and are delighted to strengthen the relationship. Our technology provides a rapid, easy to use, efficient method of labelling antibodies and we are confident it will serve Cell Guidance Systems very well in the development and production of their TRIFic detection assay kits. This latest agreement follows a number of license and supply agreements with various partners for Lightning-Link, underlining the increasing demand in academia and industry for our proprietary solutions, which help drive the life sciences research sector.”
Dr Laur-Alexandru Botos, Senior Research Scientist at Cell Guidance Systems said: “TRIFic kit is an exquisitely sensitive europium time resolved immunofluorescence assay for exosome markers. The Lightning-Link® Rapid Biotin technology is used to generate stable biotin conjugates as components of this platform. We have found Expedeon’s cutting edge technologies to be reliable and meet the high standards that our customers demand, and will be invaluable in ensuring the TRIFic detection assay kits enable researcher to save time and costs.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance